MindMed | Investor Presentation Deck | 32 slides

MindMed · 2023-09
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

32
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
The slide provides a high-level summary of the company's pipeline and financial runway.summarize
04
Uses a visual icon array to represent the '1 in 4' statistic.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
05
The slide uses a Gantt-style chart to show the progress of various drug candidates.plan_implementation
Open slide detailLoop · Cost Of Inaction
06
The slide uses a circular flywheel diagram to represent the IP strategy and a horizontal bar chart to illustrate market exclusivity duration.present_framework
Open slide detailLoop · Cost Of Inaction
07
The slide uses a simple list format to highlight two key upcoming clinical milestones.plan_implementation
Open slide detailLoop · Cost Of Inaction
08
Uses a brain diagram to map specific therapeutic areas to clinical evidence points.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
09
Uses scientific visualization to illustrate the drug's impact on brain function.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
10
The slide uses a process flow diagram to illustrate the biological mechanism of action.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
11
Uses a nested circle diagram to visualize the funnel of patients from total prevalence to treatment non-responders.frame_problem
Open slide detailLoop · Cost Of Inaction
12
The slide uses a table to establish clinical credibility for the MM-120 program by citing historical and contemporary research.cite_precedent
13
The slide presents clinical trial data (STAI-G scores) over 24 weeks, highlighting significant symptom reduction and safety profile.show_traction
Open slide detailBeat · Traction
14
The slide uses a timeline-based diagram to illustrate the clinical trial protocol.plan_implementation
Open slide detailBeat · Traction
15
The slide uses a linear process flow to describe the clinical care delivery model.present_solution
16
The slide uses a timeline to map specific digital product categories to clinical development stages.present_framework
17
The slide uses a process-oriented layout to describe the regulatory and commercialization pathway.plan_implementation
18
The slide outlines the strategic rationale for a specific clinical trial phase.plan_implementation
19
The slide outlines a clinical trial design (MMED007) using a timeline-based visualization.plan_implementation
20
plan_implementation
Open slide detailLoop · Quick Win Big Bet
21
The slide uses a biological process diagram to explain the drug's mechanism of action (MOA).present_solution
Open slide detailLoop · Quick Win Big Bet
22
The slide uses a bar chart to bridge the gap between the problem (no drugs) and the solution (R(-)-MDMA alignment with patient needs).frame_problem
23
The slide uses a bar chart to demonstrate the therapeutic index advantage of the R-enantiomer.present_solution
24
The chart shows improvement in social anxiety at 1 month and 6 months, indicating durability of effect.show_traction
25
transition
26
The slide highlights three pillars of collaboration: discovery engine, drug delivery, and clinical testing.present_solution
27
The slide highlights a strategic partnership and the resulting research pipeline.present_solution
28
The slide uses a grid layout to associate each executive with a set of logos representing their past experience.other
Open slide detailBeat · Team
29
The slide highlights the depth of experience by listing previous company affiliations for each leader.other
Open slide detailBeat · Team
30
The slide uses a logo-grid approach to establish credibility through past professional experience.cite_precedent
Open slide detailBeat · Team
31
The slide uses a bulleted list format to highlight core business strengths and specific drug development programs (MM-120 and MM-402).summarize
32
This appears to be a section divider or closing slide.filler